Candel Therapeutics, Inc. (CADL)
NasdaqGM · USD · Healthcare · Biotechnology
$7.79 (-2.99%) as of
Key statistics
- Market cap
- 596.08M
- Forward P/E
- -12.46
- EPS (TTM)
- -1.46
- Dividend yield
- 0.00%
- 52-week range
- 4.35 – 14.00
- Beta
- -0.31
- Profit margin
- 0.00%
- Analyst target
- $22.11
- Volume
- 848.18k
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Needham, MA, United States
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.